South Carolina Senate Bill S1039

South Carolina 2025-2026 Regular Session

• Introduced: 3/19/26
• Refer: 3/19/26

Caption

Schedule I substances

Summary

S1039 amends South Carolina’s controlled substances schedule by adding “substituted tryptamines” to Schedule I under Section 44-53-190 of the South Carolina Code. The bill defines substituted tryptamines broadly as compounds built on a tryptamine/indole-ethanamine structure and lists numerous examples, including DMT, DET, 5-MeO-DMT, 5-MeO-DiPT, DiPT, DPT, and several hydroxy- and acetoxy-substituted variants. It also retains the existing Schedule I hallucinogen and synthetic cannabinoid language already in the statute. The practical effect is to expand the state’s prohibition on possession, manufacture, distribution, and other controlled-substance activity involving these compounds, unless specifically excepted. By placing substituted tryptamines in Schedule I, the bill treats them as substances with a high potential for abuse and no accepted medical use under state law, aligning South Carolina’s controlled-substance list more explicitly with emerging psychedelic and designer-drug compounds. The act would take effect upon approval by the Governor.

Impact

The bill amends Section 44-53-190(D) of the South Carolina Code, which governs Schedule I hallucinogenic substances, by adding a new category for substituted tryptamines and enumerating many specific compounds and analogs. This would broaden the scope of substances covered by South Carolina’s Schedule I drug laws and give law enforcement and prosecutors clearer statutory authority over a wider range of psychedelic tryptamines and related analogs. Affected parties include manufacturers, distributors, possessors, and potentially researchers or medical entities unless an exception applies under other law.

Sentiment

No committee transcripts or recorded votes were provided, so there is no direct evidence of debate or opposition in the available record. Based on the bill text alone, the measure appears to be a straightforward drug-scheduling update with a public-safety and enforcement focus. The absence of recorded controversy suggests it may have been treated as a technical or preventive controlled-substances amendment rather than a highly contested policy change.

Contention

The main substantive issue is the breadth of the new Schedule I category. The bill uses a chemical-structure-based definition that captures a wide range of naturally occurring and synthetic tryptamines, which can raise concerns about overbreadth, impacts on scientific research, and whether some compounds might have legitimate medical or therapeutic interest. On the other hand, supporters would likely view the expansion as necessary to keep pace with designer drugs and to prevent loopholes in existing controlled-substance law. No specific legislators, agencies, or stakeholder groups are identified in the available materials.